Want to see JP:4527 full AI Analyst Report?
4527 Stock Chart & Stats
¥2560.00
-¥51.00(-1.80%)
At close: 4:00 PM EST
¥2560.00
-¥51.00(-1.80%)
Day’s Range― - ―
52-Week Range¥2,052.00 - ¥2,703.00
Previous CloseN/A
Volume733.70K
Average Volume (3M)643.03K
Market Cap
¥564.73B
Enterprise Value¥539.70K
Total Cash (Recent Filing)¥86.82B
Total Debt (Recent Filing)¥60.24B
Price to Earnings (P/E)16.3
Beta0.44
Next Earnings
Aug 06, 2026EPS Estimate
39.86Next Dividend Ex-DateN/A
Dividend Yield1.53%
Share Statistics
EPS (TTM)151.56
Shares Outstanding236,178,310
10 Day Avg. Volume564,110
30 Day Avg. Volume643,026
Financial Highlights & Ratios
PEG Ratio1.40
Price to Book (P/B)1.80
Price to Sales (P/S)1.58
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,950.00Price Target Upside15.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)157
Revenue Forecast (FY)¥367.78B
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue GrowthConsistent multi-year revenue growth (181.1B to 343.7B, 2021–2026) indicates durable demand and successful expansion of OTC, eye-care and skincare lines. Sustained top-line momentum increases scale economies, funds R&D and marketing, and supports international rollouts over years.
Consistent Profitability & ROEMaintaining net margins near ~10% alongside ROE of ~11–13% demonstrates persistent profitability and efficient capital allocation. That reliable return profile supports ongoing reinvestment, steady dividend capacity and resilience versus cyclical volatility in consumer healthcare.
Rising Free Cash FlowFree cash flow rising from 11.3B to 36.3B and covering roughly 68–76% of net income demonstrates solid cash-generation capacity. Persistent FCF enables internal funding for capex, product development, dividends and selective M&A without heavy reliance on external financing over the medium term.
Bears Say
Margin Compression Since 2024Margin compression across gross, operating and EBITDA margins since 2024 signals rising input costs or adverse product-mix shifts. If persistent, this reduces operating leverage, constrains margin expansion opportunities and forces trade-offs between pricing, marketing and long-term brand investment.
Step-up In Debt Post-2024Debt increased materially from ~12.8B to ~60B after 2024, reducing a previously conservative balance-sheet stance. Even with reported leverage still modest (~0.20), the step-up raises interest exposure, narrows strategic optionality and limits flexibility for opportunistic M&A or defensive spending.
Weak OCF Conversion & Uneven FCFOperating cash-flow conversion near 0.35–0.41 and uneven FCF (negative in 2021, modest in 2025) point to volatile working-capital dynamics and inconsistent cash quality. That variability complicates planning, may weaken resilience in downturns and could increase reliance on external funding when cycles turn.
Rohto Pharmaceutical Co News
4527 FAQ
What was Rohto Pharmaceutical Co Ltd’s price range in the past 12 months?
Rohto Pharmaceutical Co Ltd lowest stock price was ¥2052.00 and its highest was ¥2703.00 in the past 12 months.
What is Rohto Pharmaceutical Co Ltd’s market cap?
Rohto Pharmaceutical Co Ltd’s market cap is ¥564.73B.
When is Rohto Pharmaceutical Co Ltd’s upcoming earnings report date?
Rohto Pharmaceutical Co Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 19 days.
How were Rohto Pharmaceutical Co Ltd’s earnings last quarter?
Rohto Pharmaceutical Co Ltd released its earnings results on May 13, 2026. The company reported ¥26.41 earnings per share for the quarter, missing the consensus estimate of ¥30.36 by -¥3.95.
Is Rohto Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Rohto Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Rohto Pharmaceutical Co Ltd pay dividends?
Rohto Pharmaceutical Co Ltd pays a Semiannually dividend of ¥25 which represents an annual dividend yield of 1.53%. See more information on Rohto Pharmaceutical Co Ltd dividends here
What is Rohto Pharmaceutical Co Ltd’s EPS estimate?
Rohto Pharmaceutical Co Ltd’s EPS estimate is 39.86.
How many shares outstanding does Rohto Pharmaceutical Co Ltd have?
Rohto Pharmaceutical Co Ltd has 236,178,310 shares outstanding.
What happened to Rohto Pharmaceutical Co Ltd’s price movement after its last earnings report?
Rohto Pharmaceutical Co Ltd reported an EPS of ¥26.41 in its last earnings report, missing expectations of ¥30.36. Following the earnings report the stock price went up 0.496%.
Which hedge fund is a major shareholder of Rohto Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4527
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rohto Pharmaceutical Co Ltd
Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global entity engaged in the development, manufacturing, and marketing of a diverse array of pharmaceutical goods, beauty products, and nutritional supplements. Their comprehensive product line includes various ophthalmic solutions such as eye drops, contact lens care products, and eye washes. For skincare, they offer facial treatments like cleansers, toners, and creams, in addition to specialized medicated preparations for the skin. The company's offerings also extend to internal medicines, encompassing digestive aids, herbal remedies, and dietary supplements. Furthermore, they supply over-the-counter medications and deliver beauty and health services via dedicated counters. The company rebranded from Yamada Pharmaceutical to Rohto Pharmaceutical Co.,Ltd. in September 1949.
4527 Stock 12 Month Forecast
Average Price Target
¥2,950.00
▲(15.23% Upside)